ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
Independent Trading Group (ITG) Inc. notice of proposed sale of Common Stock under Form 144. The filing lists proposed sale quantities of 30,000 and 186,600 shares and states 125,903,447 shares outstanding as of 06/29/2026. It also records securities acquired as compensation: 8,380 shares (08/13/2024) and 42,522 shares (11/20/2024).
The entries are shown as Restricted Stock Award acquisitions and indicate the filer is the Issuer for those awards. The filing lists securities to be sold and notes prior sales activity in the past three months.
ENDRA Life Sciences Inc. has adopted an Amended and Restated Certificate of Incorporation for Noble Africa Inc., setting a new capital structure and governance framework under Delaware law. The charter authorizes 1,250,000,000 shares split into dual‑class common stock and preferred stock.
The new structure creates Class A Common Stock with one vote per share and Class B Common Stock with ten votes per share, with automatic and voluntary conversion mechanisms into Class A. It also empowers the board to create multiple series of preferred stock, establishes a classified board, defines stockholder voting and consent rights, and includes liability protections, indemnification, corporate opportunity waivers, business combination restrictions, and Delaware‑focused forum selection clauses.
ASP Isotopes Inc. outlined a proposed merger in which its wholly owned subsidiary Noble Africa LLC would combine with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity. The combined company plans to be named Noble Africa Inc. and apply to list on Nasdaq under the ticker “NOBA.”
Alongside the merger, Noble Africa has secured commitments for a private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes as lead investor and about $30 million from other investors, with $750,000 from certain ASP Isotopes directors and management. At closing, ASP Isotopes is expected to own about 89% of the combined company, pre-closing ENDRA stockholders about 3%, and other private placement investors about 7%, with closing targeted for the third or fourth quarter of 2026, subject to regulatory and stockholder approvals and other customary conditions.
ASP Isotopes Inc. announced that Tetra4, the Renergen subsidiary developing the Virginia Gas Project in South Africa, has signed its first five-year take-or-pay contract to sell liquid helium to an Asian industrial gases company at an initial base price above $600/MCF. The agreement covers about 15% of expected Phase 1 helium capacity and helps underpin multi-year cash flow ahead of targeted commercial production in the third quarter of 2026. Phase 1 is planned to produce roughly 70 MCF/day of liquid helium and 2,500 GJ/day of LNG, with Phase 2 targeted at about 900 MCF/day of helium and 34,000 GJ/day of LNG, supported by conditional approval for up to $750 million in senior debt financing.
ASP Isotopes Inc. COO Robert Ainscow reported selling 8,438 shares of common stock in open-market transactions at a weighted average price of $6.999 per share. According to the disclosure, these "sell to cover" trades were made under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards, rather than discretionary sales. Following the transactions, Ainscow directly holds 2,281,879 ASP Isotopes shares.
ASP Isotopes Inc. filed a Rule 144 notice regarding proposed sales of Common Stock, listing 300,000 shares issued as a restricted stock award on 09/06/2024.
The filing also records an actual sale of 22,500 shares on 04/16/2026 for $117,112.50. The securities are registered for resale and were acquired as compensation.
ASP Isotopes Inc. Chairman and CEO Paul Elliot Mann reported both share sales and a new equity award. He sold a total of 251,275 shares of common stock in three open-market transactions at weighted average prices of $7.76, $7.88, and $8.29 per share. According to the disclosure, these were "sell to cover" trades under a Rule 10b5-1 plan to cover tax withholding on quarterly vesting of a restricted stock award. Mann also received a grant of 2,233,555 shares of common stock under his employment agreement, which will vest in four equal installments over a one-year period beginning on March 1, 2026.
Ainscow Robert reported acquisition or exercise transactions in this Form 4 filing.
ASP Isotopes Inc. Chief Operating Officer Robert Ainscow received an equity grant of 800,000 shares of common stock, awarded at a stated price of $0.0000 per share as compensation. Following this grant, he directly holds 2,290,317 common shares. The award will vest in semi-annual installments over four years, subject to applicable vesting conditions.